Literature DB >> 24515275

A practical approach to remote longitudinal follow-up of Parkinson's disease: the FOUND study.

Caroline M Tanner1, Cheryl C Meng, Bernard Ravina, Anthony Lang, Roger Kurlan, Kenneth Marek, David Oakes, John Seibyl, Emily Flagg, Lisa Gauger, Dolores D Guest, Christopher G Goetz, Karl Kieburtz, Diane DiEuliis, Stanley Fahn, Robin A Elliott, Ira Shoulson.   

Abstract

The objective of this study was to examine a remote method for maintaining long-term contact with Parkinson's disease (PD) patients participating in clinical studies. Long-term follow-up of PD patients is needed to fill critical information gaps on progression, biomarkers, and treatment. Prospective in-person assessment can be costly and may be impossible for some patients. Remote assessment using mail and telephone contact may be a practical follow-up method. Patients enrolled in the multi-center Longitudinal and Biomarker Study in Parkinson's Disease (LABS-PD) in-person follow-up study in 2006 were invited to enroll in Follow-up of Persons With Neurologic Diseases (FOUND), which is overseen by a single center under a separate, central institutional review board protocol. FOUND uses mailed questionnaires and telephone interviews to assess PD status. FOUND follow-up continued when LABS-PD in-person visits ended in 2011. Retention and agreement between remote and in-person assessments were determined. In total, 422 of 499 (84.5%) of eligible patients volunteered, AND 96% of participants were retained. Of 60 patients who withdrew consent from LABS-PD, 51 were retained in FOUND. Of 341 patients who were active in LABS-PD, 340 were retained in FOUND (99.7%) when the in-person visits ceased. Exact agreement between remote and in-person assessments was ≥ 80% for diagnosis, disease features (eg, dyskinesias), and PD medication. Correlation between expert-rated and self-reported Unified Parkinson's Disease Rating Scale and Movement Disorder Society Unified Parkinson's Disease Rating Scale, which were examined at times separated by several months, was moderate or substantial for most items. Retention was excellent using remote follow-up of research participants with PD, providing a safety net when combined with in-person visits, and also is effective as a stand-alone assessment method, providing a useful alternative when in-person evaluation is not feasible.
© 2014 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Parkinson's disease; follow-up; longitudinal

Mesh:

Year:  2014        PMID: 24515275      PMCID: PMC5656448          DOI: 10.1002/mds.25814

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  37 in total

1.  Prospective assessment of falls in Parkinson's disease.

Authors:  B R Bloem; Y A Grimbergen; M Cramer; M Willemsen; A H Zwinderman
Journal:  J Neurol       Date:  2001-11       Impact factor: 4.849

2.  Testing the homogeneity of kappa statistics.

Authors:  A Donner; M Eliasziw; N Klar
Journal:  Biometrics       Date:  1996-03       Impact factor: 2.571

Review 3.  Identifying, recruiting, and retaining seriously-ill patients and their caregivers in longitudinal research.

Authors:  Karen E Steinhauser; Elizabeth C Clipp; Judith C Hays; Maren Olsen; Robert Arnold; Nicholas A Christakis; Jennifer Hoff Lindquist; James A Tulsky
Journal:  Palliat Med       Date:  2006-12       Impact factor: 4.762

4.  Factors influencing the participation of older people in clinical trials - data analysis from the MAVIS trial.

Authors:  P Fearn; A Avenell; S McCann; A C Milne; G Maclennan
Journal:  J Nutr Health Aging       Date:  2010-01       Impact factor: 4.075

5.  Problematic variation in local institutional review of a multicenter genetic epidemiology study.

Authors:  Rita McWilliams; Julie Hoover-Fong; Ada Hamosh; Suzanne Beck; Terri Beaty; Garry Cutting
Journal:  JAMA       Date:  2003-07-16       Impact factor: 56.272

6.  Randomized controlled clinical trial of "virtual house calls" for Parkinson disease.

Authors:  E Ray Dorsey; Vinayak Venkataraman; Matthew J Grana; Michael T Bull; Benjamin P George; Cynthia M Boyd; Christopher A Beck; Balaraman Rajan; Abraham Seidmann; Kevin M Biglan
Journal:  JAMA Neurol       Date:  2013-05       Impact factor: 18.302

7.  Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial.

Authors:  Connie Marras; Michael P McDermott; Paula A Rochon; Caroline M Tanner; Gary Naglie; Anthony E Lang
Journal:  Mov Disord       Date:  2008-04-15       Impact factor: 10.338

8.  A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease.

Authors: 
Journal:  Neurology       Date:  2006-02-15       Impact factor: 9.910

9.  Risk factors for somnolence, edema, and hallucinations in early Parkinson disease.

Authors:  Kevin M Biglan; Robert G Holloway; Michael P McDermott; Irene H Richard
Journal:  Neurology       Date:  2007-07-10       Impact factor: 9.910

10.  A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease.

Authors:  Cindy Zadikoff; Susan H Fox; David F Tang-Wai; Teri Thomsen; Rob M A de Bie; Pettarusup Wadia; Janis Miyasaki; Sarah Duff-Canning; Anthony E Lang; Connie Marras
Journal:  Mov Disord       Date:  2008-01-30       Impact factor: 10.338

View more
  8 in total

Review 1.  Therapeutic approaches to Huntington disease: from the bench to the clinic.

Authors:  Nicholas S Caron; E Ray Dorsey; Michael R Hayden
Journal:  Nat Rev Drug Discov       Date:  2018-09-21       Impact factor: 84.694

Review 2.  Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2017-12-08       Impact factor: 3.575

Review 3.  Novel methods and technologies for 21st-century clinical trials: a review.

Authors:  E Ray Dorsey; Charles Venuto; Vinayak Venkataraman; Denzil A Harris; Karl Kieburtz
Journal:  JAMA Neurol       Date:  2015-05       Impact factor: 18.302

4.  Feasibility of Virtual Research Visits in Fox Trial Finder.

Authors:  E Ray Dorsey; Joseph D Wagner; Michael T Bull; Ashley Rizzieri; Justin Grischkan; Meredith A Achey; Todd Sherer; Sohini Chowdhury; Claire Meunier; Lily Cappelletti; Charlotte Rocker; Irene H Richard; Heidi Schwarz; Gail Kang; Stacy H Ahmad; Rachel A Biemiller; Kevin M Biglan
Journal:  J Parkinsons Dis       Date:  2015       Impact factor: 5.568

Review 5.  Efficacy and safety of Tai Chi for Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Xiaojia Ni; Shaonan Liu; Fuchang Lu; Xiaogeng Shi; Xinfeng Guo
Journal:  PLoS One       Date:  2014-06-13       Impact factor: 3.240

6.  Simulating the progression of brain structural alterations in Parkinson's disease.

Authors:  Chang-Hyun Park; Na-Young Shin; Sang-Won Yoo; Haeseok Seo; Uicheul Yoon; Ji-Yeon Yoo; Kookjin Ahn; Joong-Seok Kim
Journal:  NPJ Parkinsons Dis       Date:  2022-06-28

7.  Video research visits for atypical parkinsonian syndromes among Fox Trial Finder participants.

Authors:  Christopher G Tarolli; Grace A Zimmerman; Steven Goldenthal; Blake Feldman; Sarah Berk; Bernadette Siddiqi; Catherine M Kopil; Sohini Chowdhury; Kevin M Biglan; E Ray Dorsey; Jamie L Adams
Journal:  Neurol Clin Pract       Date:  2020-02

8.  Comparison of an Online-Only Parkinson's Disease Research Cohort to Cohorts Assessed In Person.

Authors:  Lana M Chahine; Iris Chin; Chelsea Caspell-Garcia; David G Standaert; Ethan Brown; Luba Smolensky; Vanessa Arnedo; Daisy Daeschler; Lindsey Riley; Monica Korell; Roseanne Dobkin; Ninad Amondikar; Stephen Gradinscak; Ira Shoulson; Marissa Dean; Kevin Kwok; Paul Cannon; Kenneth Marek; Catherine Kopil; Caroline M Tanner; Connie Marras
Journal:  J Parkinsons Dis       Date:  2020       Impact factor: 5.520

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.